entertainment -WSS

entertainment

author：comprehensive 2025-09-27 12:47:36 - browse：54

Adam's take main illustration — Molly Ferguson/STAT

Novartis said Monday that it intends to buy MorphoSys for just under $3 billion. The deal will not close. Six months from now, or sooner, Novartis will walk away — slightly embarrassed but otherwise unscathed — happy to pay a small breakup fee to MorphoSys to avoid owning a drug for myelofibrosis that regulators turned away.

MorphoSys will not fare as well from the breakup. Its future, and that of the drug called pelabresib at the center of the deal, will be thrown into limbo.

This is all speculation on my part, but it’s supported by separate conversations with two people familiar with pelabresib and the debate inside Novartis over the MorphoSys acquisition. They requested anonymity to discuss confidential matters.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： After affirmative action ruling, medical educators look to 'holistic review'
Next article： See how much Covid

explore

WSS

Advocates call out 'SNL' over stereotypes, errors in sickle cell skit

Editas, Vertex strike deal on CRISPR

The Pandemic Treaty must support building strong health systems

Can sheer will power keep patients alive in their dying hours?

ASCO24: AstraZeneca won cancer’s big meeting. Can it fulfill its $80B ambition?

Medicare Advantage beneficiaries sue Humana over algorithm use

leisure time

entertainment

Wikipedia

Walensky prepares to leave CDC — and Congress — behind

At ASCO, AstraZeneca reports strong data for breast cancer drug

How to save PrEP access — and even expand it

Drinking less cuts risk of oral cavity, esophageal cancer: Report

At least 13 dead in Texas as scorching temps continue

ASCO: Palliative care found as helpful given virtually as in person

Jerome Adams on the need for new antivirals for Covid

Intellia reports positive results for its CRISPR

Sports medicine is finally prioritizing gender equality

What STAT readers think about the FDA and patient advocacy

Wikipedia

ASCO24: AstraZeneca won cancer’s big meeting. Can it fulfill its $80B ambition?

Cord blood banking comes at a high cost to babies

Prime Medicine, Myeloid Therapeutics clash over genome

ASCO24: AstraZeneca won cancer’s big meeting. Can it fulfill its $80B ambition?

ASCO Daily Recap: Safety data from Novartis, survival from Pfizer

ASCO: AstraZeneca's Tagrisso greatly slowed some lung cancers

focus

explore

knowledge

leisure time